<strong>2008</strong> CLINICAL PRACTICE GUIDELINES S60 Med. 1998;338:861-866. 44. Meymeh RH, Wooltorton E. <strong>Diabetes</strong> drug pioglitazone (Actos): risk of fracture. CMAJ. 2007;177:723-724. 45. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443. 46. Kahn SE, Zinman B, Lachin JM, et al; A <strong>Diabetes</strong> Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A <strong>Diabetes</strong> Outcome Progression Trial. <strong>Diabetes</strong> Care. <strong>2008</strong>;31:845-851. 47. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. <strong>Diabetes</strong> Care. 2002;25:1123-1128. 48. Kelley DE, Bray GA, Pi-Sunyer FX, et al. <strong>Clinical</strong> efficacy of orlistat therapy in overweight and obese patients with insulintreated type 2 diabetes: A 1-year randomized controlled trial. <strong>Diabetes</strong> Care. 2002;25:1033-1041. 49. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. <strong>Diabetes</strong> Care. 1998;21:1288- 1294. 50. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. <strong>Diabetes</strong> Care. 2005;28:942-999. 51. Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. <strong>Diabetes</strong> Obes Metab. 2000;2:105-112. 52. UK Prospective <strong>Diabetes</strong> Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865. 53. Avandia – Highlights of Prescribing Information. March <strong>2008</strong>. Research Triangle Park, NC: GlaxoSmithKline. Available at: http://www.gsk.com/products/prescription_medicines/us /medicines-ae.htm. Accessed September 1, <strong>2008</strong>. 54. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471. 55. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298: 1189-1195. 56. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone <strong>Clinical</strong> Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289. 57. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiovascular Outcomes – An interim analysis. N Engl J Med. 2007;357:28-38. 58. The Action to Control Cardiovascular Risk in <strong>Diabetes</strong> Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. <strong>2008</strong>;358:2545-2559. 59. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426-1433. 60. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A metaanalysis of the randomized placebo-controlled trials. Arch Intern Med. 1996;156:259-264. 61. Yu JG, Krusynska MT, Mulford MI, et al. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. <strong>Diabetes</strong>. 1999;48:2414-2421. 62. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. <strong>Diabetes</strong> Care. 2006;29: 1282-1287. 63. American <strong>Diabetes</strong> <strong>Association</strong>. Implications of the United Kingdom Prospective <strong>Diabetes</strong> Study. <strong>Diabetes</strong> Care. 1998;21: 2180-2184. 64. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. <strong>Diabetes</strong> Care. 1995;18:1113-1123. 65. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. <strong>Diabetes</strong> Care. 1989;12:203-208. 66. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:1249-1255. 67. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther. 1997;19:62-72. 68. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. <strong>Diabetes</strong> Care. 2000;23:1130-1136. 69. Fritsche A, Schweitzer MA, Haring HU, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Int Med. 2003;138:952-959. 70. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. <strong>Diabetes</strong> Care. 2005;28:254-259. 71. Horvath K, Jeitler K, Berghold A, et al. A long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review). Cochrane Database Syst Rev. 2007;(2):CD005613. 72. Roach P,Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel prota-
mine-based insulin lispro formulation. Humalog Mix25 Study Group. <strong>Diabetes</strong> Care. 1999;22:1258-1261. 73. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19:393-399. 74. Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. <strong>Diabetes</strong> Care. 2004;27:2874-2880. 75. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther. 2003;25:472-484. 76. Ristic S, Collober-Maugeais C, Pecher E, et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med. 2006;23:757-762. 77. Ross SA, Zinman B, Campos RV, et al. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med. 2001;24:292-298. 78. Rosenfalck AM,Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41-46. S61 MANAGEMENT
Change language